STAA logo

STAAR SURGICAL CO

STAANASDAQ
๐Ÿ† #2460 by market capEarnings Nov 4US Equity
$22.32โ–ฒ $1.55 (+6.95%)
Live
๐Ÿ””
Track STAA
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 7.0%
7dโ–ฒ 8.2%
14dโ–ผ 0.5%
30dโ–ฒ 1.0%
ytdโ–ผ 3.3%
1yโ–ผ 16.9%
๐ŸฆMarket Cap
$1.11B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-23.7%
Declining
๐Ÿ“ŠGross Margin
76.2%
High
๐Ÿ’ตFCF Margin
-2.0%
Thin
โš–๏ธP/S Ratio
3.0x
Fair
Otter Score
76
Good

Trading Snapshot

Day Range
$22.09 โ€“ $22.49
52-Week Range
$15.59 โ€“ $35.87
Volume
$2.93B
Avg Volume
$3.03B
Shares Outstanding
49.8M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$239M
Last Q Revenue
$94M
P/E Ratio
256.4
P/S Ratio
3.0x
EPS (TTM)
$0.08
Dividend Yield
0.00%
Dilution (1yr)
+4.0%

Why Investors Own STAA

  • โœ“High-growth profile โ€” revenue up +50.6% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 43% gross margin and 25% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

STAA logo

STAAR SURGICAL CO

STAA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$239Mโ–ผ โˆ’23.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
76.2%โ–ผ โˆ’0.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$46Mโ–ฒ +264.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$40Mโ–ฒ +422.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
51.5Mโ–ฒ +4.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$113Mโ–ผ โˆ’$24M YoY
StockOtter ยท stockotter.space

About STAAR SURGICAL CO

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Good
76/100

Analyst Price Target

โ“˜
Average Target
$24.60
โ–ฒ +10.2% Upside
High Target$30.59
Low Target$22.91
Based on 20 analysts

Latest News & Updates

Benzingaยท5h ago

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

247 Wallstยท8h ago

Here Are Tuesdayโ€™s Top Wall Street Analyst Research Calls: AutoZone, Baker Hughes, FS KKR Capital, Kroger, Netflix, PepsiCo, Ryder Systems, SpaceX, Warner Bros. Discovery, and More

Markets opened Tuesday on edge as surging oil prices, climbing Treasury yields, and a rejected Iran ceasefire rattled traders heading into the final stretch of Q3. Find out which major names on Wall Street got upgraded,

Defense Worldยท10h ago

Contrasting Sensus Healthcare (NASDAQ:SRTS) and STAAR Surgical (NASDAQ:STAA)

Sensus Healthcare (NASDAQ: SRTS - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based o

The Motley Foolยท3d ago

Why Staar Surgical Stock Soared Today

It anticipates this will run for one year. The company's recent fundamentals have been rather impressive.

Business Wireยท5d ago

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVOโ„ข family of Implantable Collamerยฎ Lenses (EVO ICLโ„ข) for vision correction, today announced that it

GuruFocusยท5d ago

Is Staar Surgical Co (STAA) a Bargain After 4.1% Drop? GF Value Says Undervalued

On September 23, 2026, Staar Surgical Co (STAA) shares fell by 4.1%, closing at $19.80. The stock has had a turbulent year, trading within a 52-week range of $1